This biotech’s stock could double if its treatment for major depressive disorder succeeds, says Mizuho
Nov 13, 2024
Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when the company reports data from a late-stage trial of its treatment for major depressive disorder, or MDD, later this year.
https://www.marketwatch.com/story/this-biotechs-stock-could-double-if-its-treatment-for-major-depressive-disorder-succeeds-says-mizuho-67813e9a?mod=mw_rss_topstories
Respond, make new discussions, see other discussions and customize your news...

To add this website to your home screen:

1. Tap tutorialsPoint

2. Select 'Add to Home screen' or 'Install app'.

3. Follow the on-scrren instructions.

Feedback
FAQ
Privacy Policy
Terms of Service